Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases
CA 2492655 A1 · Owner: Centre National De La Recherche Scientifique (Cnrs) · Inventors: Rougon, Genevieve; Castellani, Valerie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to peptides comprising the sequence ASNKL (SEQ ID N~ 1), inducing attraction of the axonal growth in presence of the semaphorin (Sema3A), L1 and NP-1 proteins and their use for the manufacture of a drug for neuronal/axonal regeneration or for treating neurodegenerative diseases. The present invention also includes a method for identifying a compound able to bind the NP-1, a method for identifying a compound able to revert the repulsory effect of Sema3A on the axonal growth from a suited cell or methods to screen for molecules capable of blocking Sema3A- induced endocytosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 18, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 18, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 18, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.